Jacobs Levy Equity Management’s Bioventus BVS Stock Holding History

Jacobs Levy Equity Management’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$508K	Buy	53,854 +29,155	+118%	+$278K	﹤0.01%	823
2026 Q1	$226K	Sell	24,699 -96,574	-80%	-$810K	﹤0.01%	904
2025 Q4	$902K	Sell	121,273 -19,694	-14%	-$142K	﹤0.01%	700
2025 Q3	$943K	Buy	140,967 +4,605	+3%	+$32K	﹤0.01%	733
2025 Q2	$903K	Buy	136,362 +27,147	+25%	+$193K	﹤0.01%	774
2025 Q1	$999K	Sell	109,215 -62,447	-36%	-$624K	﹤0.01%	811
2024 Q4	$1.8M	Sell	171,662 -23,946	-12%	-$283K	0.01%	610
2024 Q3	$2.34M	Sell	195,608 -102,407	-34%	-$885K	0.01%	571
2024 Q2	$1.71M	Hold	298,015	–	–	0.01%	633
2024 Q1	$1.55M	Sell	298,015 -30,814	-9%	-$151K	0.01%	636
2023 Q4	$1.73M	Sell	328,829 -37,354	-10%	-$148K	0.01%	624
2023 Q3	$1.21M	Buy	366,183 +300,450	+457%	+$1.05M	0.01%	642
2023 Q2	$190K	Sell	65,733 -88,687	-57%	-$170K	﹤0.01%	930
2023 Q1	$165K	Buy	+154,420	New	+$295K	﹤0.01%	914
2022 Q1	–	Sell	-52,004	Closed	-$754K	–	1002
2021 Q4	$754K	Buy	+52,004	New	+$739K	0.01%	782

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JIC

Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jacobs Levy Equity Management's BVS Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Bioventus (BVS) stake by 118% in Q2 2026, buying an estimated $278K and bringing the position to 53,854 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #823.

Jacobs Levy Equity Management first reported a position in BVS in Q4 2021 and has held it in 15 quarters since. The position peaked at $2.34M in Q3 2024. 156 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

Jacobs Levy Equity Management held 53,854 shares of Bioventus worth $508K as of Q2 2026.
Jacobs Levy Equity Management bought 29,155 Bioventus shares in Q2 2026, an estimated $278K.
Bioventus made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #823 holding.
Jacobs Levy Equity Management first reported a position in Bioventus in Q4 2021 and has held it in 15 quarters since.
Jacobs Levy Equity Management's Bioventus position peaked at $2.34M in Q3 2024.
156 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.